Design is the Key to More Sustainable ProductionARCO, Italy, Aug. 26, 2024 -- Aquafil SpA (ECNLF:OTCQX - ECNL:IM), based in Arco (TN) Italy and a pioneer of the circular economy, today released its second in a series of monographs that illustrate how we can design...
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced today that they will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal...
ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+
One of the most robust forms of intellectual property protection, a composition of matter patent grants ChromaDex exclusive rights to the disodium salt form of NMNH LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide...
ChromaDex Corporation Reports Second Quarter 2024 Financial Results
Total net sales of $22.7 million, up 12% year-over-year, gross margin of 60.2%, lower operating expenses, resulting in approximately breakeven net loss and positive Adjusted EBITDA of $1.6 million for the three months ended June 30, 2024. LOS ANGELES - ChromaDex Corp....
ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Interim Chief Financial Officer, James Lee, will...
Dror Ortho-Design, Inc. Launches ZSMILE User Experience Trial
JERUSALEM, Aug. 05, 2024 -- Dror Ortho-Design, Inc. ("Dror" or the "Company") (OTC PINK: DROR), an AI-based orthodontic platform company that has developed a proprietary solution to correct people's smiles by straightening teeth using pulsating air delivered by a...
ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will hold a conference call on Wednesday, August 7, 2024 at 4:30 p.m. ET to discuss its financial...
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)
Results from the at-home test kit are available to HCPs and their patients through 1health LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, launches the Niagen+ NAD+...
ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Carlos Lopez as Senior Vice President, General Counsel. Mr. Lopez will oversee the...
Dror Ortho-Design, Inc. Launches New ZSMILE Product Brand
JERUSALEM, July 17, 2024 -- Dror Ortho-Design, Inc. ("Dror" or the "Company") (OTC PINK: DROR), an AI-based orthodontic platform company that has developed a proprietary solution to correct people's smiles by straightening teeth using pulsating air delivered by a...